• Something wrong with this record ?

The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis

R. Sari Motlagh, F. Quhal, K. Mori, N. Miura, A. Aydh, E. Laukhtina, B. Pradere, PI. Karakiewicz, DV. Enikeev, M. Deuker, SF. Shariat

. 2021 ; 205 (1) : 60-67. [pub] 20200828

Language English Country United States

Document type Comparative Study, Journal Article, Meta-Analysis, Systematic Review

Persistent link   https://www.medvik.cz/link/bmc21011667

PURPOSE: Androgen deprivation therapy is a standard therapy for some patients with localized and almost all patients with metastatic prostate cancer. Although several clinical cohort studies have identified an impact of androgen deprivation therapy on cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer disease. Consequently there is still a lack of systematic review and meta-analysis regarding the impact of this risk including more recent studies. MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of the literature assessing the differential incidence of dementia and/or Alzheimer disease as outcomes in patients with prostate cancer who did vs did not receive androgen deprivation therapy. We queried PubMed® and Web of Science™ databases from January 1 to 3, 2020. We used random or fixed effects meta-analytic models in the presence or absence of heterogeneity per the I2 statistic. We performed 6 meta-analyses for all cause dementia, Alzheimer disease and all cause dementia or Alzheimer disease according to the duration of androgen deprivation therapy (up to 12 or more than 12 months). RESULTS: A total of 14 studies were selected after considering inclusion and exclusion criteria. Nine of them reported all cause dementia (ie all types of dementia including Alzheimer disease), with 8 reporting Alzheimer disease. Five studies assessed these outcomes according to the duration of androgen deprivation therapy. The risk of new onset dementia (all cause) and Alzheimer disease was higher in patients with prostate cancer who received androgen deprivation therapy compared to those who did not (HR 1.21, 95% CI 1.11-1.33 and HR 1.16, 95% CI 1.09-1.24). The risk of dementia (all cause) was higher in patients with prostate cancer who received androgen deprivation therapy for more than 12 months (HR 1.36, 95% CI 1.07-1.72); however, for those who had less than 12 months of androgen deprivation therapy exposure the difference was not statistically significant 1.06 (95% CI 0.77-1.28). There was no association between the androgen deprivation therapy duration and the risk of Alzheimer disease (HR 1.21, 95% CI 0.97-1.51 for exposure up to 12 months and HR 1.39, 95% CI 0.69-2.79 for exposure greater than 12 months). CONCLUSIONS: Men who receive androgen deprivation therapy for prostate cancer have an increased risk of dementia and/or Alzheimer disease compared to men who do not receive androgen deprivation therapy; this was more pronounced when androgen deprivation therapy was given longer than 12 months.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011667
003      
CZ-PrNML
005      
20210713152021.0
007      
ta
008      
210420s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/JU.0000000000001341 $2 doi
035    __
$a (PubMed)32856962
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sari Motlagh, Reza $u Department of Urology, Medical University of Vienna, Vienna, Austria
245    14
$a The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis / $c R. Sari Motlagh, F. Quhal, K. Mori, N. Miura, A. Aydh, E. Laukhtina, B. Pradere, PI. Karakiewicz, DV. Enikeev, M. Deuker, SF. Shariat
520    9_
$a PURPOSE: Androgen deprivation therapy is a standard therapy for some patients with localized and almost all patients with metastatic prostate cancer. Although several clinical cohort studies have identified an impact of androgen deprivation therapy on cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer disease. Consequently there is still a lack of systematic review and meta-analysis regarding the impact of this risk including more recent studies. MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of the literature assessing the differential incidence of dementia and/or Alzheimer disease as outcomes in patients with prostate cancer who did vs did not receive androgen deprivation therapy. We queried PubMed® and Web of Science™ databases from January 1 to 3, 2020. We used random or fixed effects meta-analytic models in the presence or absence of heterogeneity per the I2 statistic. We performed 6 meta-analyses for all cause dementia, Alzheimer disease and all cause dementia or Alzheimer disease according to the duration of androgen deprivation therapy (up to 12 or more than 12 months). RESULTS: A total of 14 studies were selected after considering inclusion and exclusion criteria. Nine of them reported all cause dementia (ie all types of dementia including Alzheimer disease), with 8 reporting Alzheimer disease. Five studies assessed these outcomes according to the duration of androgen deprivation therapy. The risk of new onset dementia (all cause) and Alzheimer disease was higher in patients with prostate cancer who received androgen deprivation therapy compared to those who did not (HR 1.21, 95% CI 1.11-1.33 and HR 1.16, 95% CI 1.09-1.24). The risk of dementia (all cause) was higher in patients with prostate cancer who received androgen deprivation therapy for more than 12 months (HR 1.36, 95% CI 1.07-1.72); however, for those who had less than 12 months of androgen deprivation therapy exposure the difference was not statistically significant 1.06 (95% CI 0.77-1.28). There was no association between the androgen deprivation therapy duration and the risk of Alzheimer disease (HR 1.21, 95% CI 0.97-1.51 for exposure up to 12 months and HR 1.39, 95% CI 0.69-2.79 for exposure greater than 12 months). CONCLUSIONS: Men who receive androgen deprivation therapy for prostate cancer have an increased risk of dementia and/or Alzheimer disease compared to men who do not receive androgen deprivation therapy; this was more pronounced when androgen deprivation therapy was given longer than 12 months.
650    _2
$a Alzheimerova nemoc $x chemicky indukované $x epidemiologie $x prevence a kontrola $7 D000544
650    _2
$a antagonisté androgenů $x aplikace a dávkování $x škodlivé účinky $7 D000726
650    _2
$a hormonální protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D018931
650    _2
$a kognice $x účinky léků $7 D003071
650    _2
$a demence $x chemicky indukované $x epidemiologie $x prevence a kontrola $7 D003704
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory prostaty $x farmakoterapie $x patologie $7 D011471
650    _2
$a hodnocení rizik $x statistika a číselné údaje $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria ; King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria ; Department of Urology, Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria ; Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Aydh, Abdulmajeed $u Department of Urology, Medical University of Vienna, Vienna, Austria ; King Faisal Medical City, Abha, Saudi Arabia
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria ; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria ; Department of Urology, University Hospital of Tours, Tours, France
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
700    1_
$a Enikeev, Dmitry V $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Deuker, Marina $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Weil Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Special Surgery, Jordan University Hospital, University of Jordan, Amman, Jordan $u European Association of Urology Research Foundation, Arnhem, Netherlands
773    0_
$w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 205, č. 1 (2021), s. 60-67
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32856962 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210713152018 $b ABA008
999    __
$a ok $b bmc $g 1650131 $s 1132046
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 205 $c 1 $d 60-67 $e 20200828 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
LZP    __
$a Pubmed-20210420
Back

Find record

Citation metrics

Archiving options